122 related articles for article (PubMed ID: 37984714)
21. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.
Kumar SK; Jacobus SJ; Cohen AD; Weiss M; Callander N; Singh AK; Parker TL; Menter A; Yang X; Parsons B; Kumar P; Kapoor P; Rosenberg A; Zonder JA; Faber E; Lonial S; Anderson KC; Richardson PG; Orlowski RZ; Wagner LI; Rajkumar SV
Lancet Oncol; 2020 Oct; 21(10):1317-1330. PubMed ID: 32866432
[TBL] [Abstract][Full Text] [Related]
22. Impact of post-ASCT maintenance therapy on outcomes in patients with newly diagnosed multiple myeloma in Connect MM.
Jagannath S; Abonour R; Durie BGM; Narang M; Terebelo HR; Gasparetto CJ; Toomey K; Hardin JW; Wagner L; Agarwal A; Srinivasan S; Kitali A; Flick ED; Sturniolo M; Rifkin RM
Blood Adv; 2018 Jul; 2(13):1608-1615. PubMed ID: 29986853
[TBL] [Abstract][Full Text] [Related]
23. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
Moreau P; Mateos MV; Berenson JR; Weisel K; Lazzaro A; Song K; Dimopoulos MA; Huang M; Zahlten-Kumeli A; Stewart AK
Lancet Oncol; 2018 Jul; 19(7):953-964. PubMed ID: 29866475
[TBL] [Abstract][Full Text] [Related]
24. Balloon kyphoplasty: an evidence-based analysis.
Medical Advisory Secretariat
Ont Health Technol Assess Ser; 2004; 4(12):1-45. PubMed ID: 23074451
[TBL] [Abstract][Full Text] [Related]
25. Effect of t (11;14) Abnormality on Outcomes of Patients With Newly Diagnosed Multiple Myeloma in the Connect MM Registry.
Gasparetto C; Jagannath S; Rifkin RM; Durie BGM; Narang M; Terebelo HR; Toomey K; Hardin JW; Wagner L; Ailawadhi S; Omel JL; Srinivasan S; Dhalla M; Catamero D; Kitali A; Agarwal A; Abonour R;
Clin Lymphoma Myeloma Leuk; 2022 Mar; 22(3):149-157. PubMed ID: 34588149
[TBL] [Abstract][Full Text] [Related]
26. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
Durie BGM; Hoering A; Abidi MH; Rajkumar SV; Epstein J; Kahanic SP; Thakuri M; Reu F; Reynolds CM; Sexton R; Orlowski RZ; Barlogie B; Dispenzieri A
Lancet; 2017 Feb; 389(10068):519-527. PubMed ID: 28017406
[TBL] [Abstract][Full Text] [Related]
27. Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study.
Raje N; Terpos E; Willenbacher W; Shimizu K; García-Sanz R; Durie B; Legieć W; Krejčí M; Laribi K; Zhu L; Cheng P; Warner D; Roodman GD
Lancet Oncol; 2018 Mar; 19(3):370-381. PubMed ID: 29429912
[TBL] [Abstract][Full Text] [Related]
28. Real-world treatment outcomes in multiple myeloma: Multicenter registry results from Finland 2009-2013.
Remes K; Anttila P; Silvennoinen R; Putkonen M; Ollikainen H; Terävä V; Sinisalo M; Kananen K; Schain F; Castren-Kortegangas P; Järvinen TM; Pisini M; Wahl F; Dixon T; Leval A
PLoS One; 2018; 13(12):e0208507. PubMed ID: 30517181
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of the frailty characteristics and clinical outcomes according to the new frailty-based outcome prediction model (Myeloma Risk Profile-MRP) in a UK real-world cohort of elderly newly diagnosed Myeloma patients.
Djebbari F; Rampotas A; Panitsas F; Lim WY; Lees C; Tsagkaraki I; Gomes AR; Prideaux S; Chen L; Prodger C; Khera A; Gray N; Ellis L; Sangha G; Eyre TA; Moore S; Kothari J; Ramasamy K
PLoS One; 2022; 17(1):e0262388. PubMed ID: 35015781
[TBL] [Abstract][Full Text] [Related]
30. Recognition of early mortality in multiple myeloma by a prediction matrix.
Terebelo H; Srinivasan S; Narang M; Abonour R; Gasparetto C; Toomey K; Hardin JW; Larkins G; Kitali A; Rifkin RM; Shah JJ
Am J Hematol; 2017 Sep; 92(9):915-923. PubMed ID: 28543165
[TBL] [Abstract][Full Text] [Related]
31. [Multiple Myeloma - Current Status in Diagnostic Testing and Therapy].
Kehrer M; Koob S; Strauss A; Wirtz DC; Schmolders J
Z Orthop Unfall; 2017 Oct; 155(5):575-586. PubMed ID: 28806822
[No Abstract] [Full Text] [Related]
32. A real-world data analysis of predictors of early mortality after a diagnosis of multiple myeloma.
Grant SJ; Wildes TM; Rosko AE; Silberstein J; Giri S
Cancer; 2023 Jul; 129(13):2023-2034. PubMed ID: 36989073
[TBL] [Abstract][Full Text] [Related]
33. Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR).
McQuilten Z; Wellard C; Moore E; Augustson B; Bergin K; Blacklock H; Harrison S; Ho PJ; King T; Quach H; Mollee P; Rosengarten B; Walker P; Wood E; Spencer A;
Br J Haematol; 2022 Sep; 198(5):830-837. PubMed ID: 35818641
[TBL] [Abstract][Full Text] [Related]
34. Impact of Socioeconomic Characteristics and Comorbidities on Therapy Initiation and Outcomes of Newly Diagnosed Multiple Myeloma: Real-World Data From a Resource-Constrained Setting.
Vargas-Serafin C; Acosta-Medina AA; Ordonez-Gonzalez I; Martínez-Baños D; Bourlon C
Clin Lymphoma Myeloma Leuk; 2021 Mar; 21(3):182-187. PubMed ID: 33414064
[TBL] [Abstract][Full Text] [Related]
35. Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial.
Mina R; Musto P; Rota-Scalabrini D; Paris L; Gamberi B; Palmas A; Aquino S; de Fabritiis P; Giuliani N; De Rosa L; Gozzetti A; Cellini C; Bertamini L; Capra A; Oddolo D; Vincelli ID; Ronconi S; Pavone V; Pescosta N; Cea M; Fioritoni F; Ballanti S; Grasso M; Zamagni E; Belotti A; Boccadoro M; Gay F
Lancet Oncol; 2023 Jan; 24(1):64-76. PubMed ID: 36528035
[TBL] [Abstract][Full Text] [Related]
36. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study.
Garassino MC; Whisenant JG; Huang LC; Trama A; Torri V; Agustoni F; Baena J; Banna G; Berardi R; Bettini AC; Bria E; Brighenti M; Cadranel J; De Toma A; Chini C; Cortellini A; Felip E; Finocchiaro G; Garrido P; Genova C; Giusti R; Gregorc V; Grossi F; Grosso F; Intagliata S; La Verde N; Liu SV; Mazieres J; Mercadante E; Michielin O; Minuti G; Moro-Sibilot D; Pasello G; Passaro A; Scotti V; Solli P; Stroppa E; Tiseo M; Viscardi G; Voltolini L; Wu YL; Zai S; Pancaldi V; Dingemans AM; Van Meerbeeck J; Barlesi F; Wakelee H; Peters S; Horn L;
Lancet Oncol; 2020 Jul; 21(7):914-922. PubMed ID: 32539942
[TBL] [Abstract][Full Text] [Related]
37. [Benefits of radiotherapy for patients with solitary plasmacytoma or multiple myeloma].
König L; Herfarth K
Radiologe; 2022 Jan; 62(1):30-34. PubMed ID: 34762165
[TBL] [Abstract][Full Text] [Related]
38. Ixazomib-based regimens for relapsed/refractory multiple myeloma: are real-world data compatible with clinical trial outcomes? A multi-site Israeli registry study.
Cohen YC; Magen H; Lavi N; Gatt ME; Chubar E; Horowitz N; Kreiniz N; Tadmor T; Trestman S; Vitkon R; Rouvio O; Shvetz O; Shaulov A; Ziv-Baran T; Avivi I
Ann Hematol; 2020 Jun; 99(6):1273-1281. PubMed ID: 32193630
[TBL] [Abstract][Full Text] [Related]
39. Persistence of myeloma protein for more than one year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of bone.
Wilder RB; Ha CS; Cox JD; Weber D; Delasalle K; Alexanian R
Cancer; 2002 Mar; 94(5):1532-7. PubMed ID: 11920511
[TBL] [Abstract][Full Text] [Related]
40. Validation of multiple myeloma risk stratification indices in routine clinical practice: Analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies.
Radocha J; Maisnar V; Pour L; Špička I; Minařík J; Szeligová L; Pavlíček P; Jungová A; Krejčí M; Pika T; Straub J; Brožová L; Stejskal L; Heindorfer A; Jindra P; Kessler P; Mikula P; Sýkora M; Wróbel M; Jarkovský J; Hájek R
Cancer Med; 2018 Aug; 7(8):4132-4145. PubMed ID: 29931775
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]